EVA Pharma Explores the Manufacturing of COVID-19 Vaccines with European and American Companies


  • Armanious: “We are willing to cooperate with all parties that will provide the Egyptian patient a head start. We are establishing a whole city to manufacture vaccines in Egypt.”
  • EVA Pharma’s CEO: “We will produce the human and veterinary vaccines. The city will be completed within 3 to 5 years & our first product, a veterinary vaccine will be released within 3 months.”
  • Ayman Al-Deib: “200 million birds will be vaccinated against influenza and Newcastle disease before winter 2021”

 

Cairo, July 28, 2020 – EVA Pharma announced its efforts at concluding cooperation agreements to manufacture a vaccine for the novel coronavirus in Egypt.

In the meantime, Dr. Riad Armanious, EVA Pharma’s CEO, said that they started communicating with various international companies, both European and American, working on the development of coronavirus vaccine and that EVA Pharma is willing and prepared to cooperate with all parties that will provide the Egyptian patient with a head start at attaining the COVID-19 vaccine.

In his press statement, earlier today, Armanious added that the manufacturing of the vaccine in Egypt will ensure its affordability to the Egyptian patient & the availability in any quantities needed by the national market in addition to its high quality.

Armanious emphasized the company’s keenness to cover the needs of the Egyptian patient while facing the coronavirus, including antiviral treatments, immunity-boosting agents, all supportive treatments in addition to the vaccine.

He clarified that his company started implementing a massive national project to build the first medical city specialized in manufacturing human and veterinary vaccines in Egypt, Africa and the middle east.

This step comes in alignment with the company’s mission to secure the needs of the Egyptian citizens as well as citizens in all the continents where the company operates. The first phase of the project will include veterinary vaccines along with the quest to produce COVID-19 vaccines after proven effective globally.

The company consulted two of the biggest international expert houses to develop construction designs of the human and veterinary vaccine plant according to the global standards, before the emerging of the novel coronavirus. The plant will contribute towards the self-sufficiency of the vaccines and provide Egypt with hard currency with the export.

Armanious added, “owning a medical city that is specialized in producing vaccines will enable Egypt to produce, with high speed and quality, vaccines against any future microbial threat; as it will also open doors to collaboration with the leading global institutes in the vaccination field including vaccines against different viruses”.

Armanious pointed that EVA Pharma’s first vaccine product will be released before the end of 2020, as it will be used to vaccinate a huge amount of birds and poultry against winter-related viruses as “influenza” and “Newcastle disease”. The project, as highlighted by Armanious, will protect almost 10% of Egypt’s poultry fortune from winter-related respiratory viruses, a number that is estimated from 100 to 200 million different birds.

The vaccine city will be complete within 3 to 5 years, the time which EVA Pharma is investing in preparing the manufacturing process of different vaccines.

From his part, Dr. Ayman Al-Deib, assistant professor in viruses at the veterinary medical college in Cairo University and the technical consultant of EVA Pharma on its veterinary vaccinations portfolio, said the company has already successfully registered two veterinary vaccines which will be its first vaccine products.

Al-Deib added, the two vaccines will be available at the national markets within 2 to 3 months at the most estimate, with the help and cooperation of the Serums and Vaccines Research Institute of Ministry of Agriculture and Land Reclamation.

Clarifying that such vaccines are usually imported, Al-Deib said that the Egyptian vaccines will reduce the influenza and Newcastle disease death toll of poultry, which resolves a big problem at the poultry industry, when a safe, high quality and affordable vaccine is available.

download as pdf


Loading